PTGS2 and colorectal cancer: Consistent with our findings, clinical trials have demonstrated that combining anti-PD-1 immunotherapy with the COX-2-specific inhibitor celecoxib enhanced therapeutic efficacy in colorectal cancer patients [44,45].